Arecor Therapeutics PLC TETRIS PHARMA LAUNCHES OGLUO(R) IN AUSTRIA
January 04 2023 - 2:00AM
RNS Non-Regulatory
TIDMAREC
Arecor Therapeutics PLC
04 January 2023
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
TETRIS PHARMA LAUNCHES OGLUO (R) IN AUSTRIA
Cambridge, UK, 4 January 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical company advancing today's therapies to
enable healthier lives, announces that subsidiary company, Tetris
Pharma Ltd, has today launched Ogluo(R) (glucagon prefilled
autoinjector pen) as a treatment for severe hypoglycaemia in
children and adults living with diabetes in Austria, the second
European launch in the Ogluo(R) European roll-out strategy.
See full Tetris Pharma announcement below:
Tetris Pharma European roll-out of Ogluo(R) continues with
launch in Austria
A new treatment option for severe hypoglycaemia for children and
adults living with diabetes
4 January 2023 - Tetris Pharma Ltd ("Tetris Pharma" or "the
Company"), a subsidiary of biopharmaceutical company, Arecor
Therapeutics plc (AIM: AREC), today announces the launch of
Ogluo(R) (glucagon prefilled autoinjector pen) in Austria as a
treatment for severe hypoglycaemia in adults, adolescent, and
children aged two years and over living with diabetes mellitus.
Ogluo(R) is a ready-to-use, ambiently stored, preparation of
glucagon to treat severe hypoglyceamia for people living with
diabetes. There are an estimated 450,000 adults living with
diabetes in Austria (IDF Atlas 10(th) Edition).
Ogluo(R) pricing has been published in Austria in the
Warenverzeichnis (the reference for all Austrian pharmacies,
insurers and wholesalers) managed by the Apotheker-Verlages(R).
Full prescribing information can be found here . Today's launch in
Austria builds on the roll-out of Ogluo(R) in Germany and Great
Britain, as part of the pan-European commercialisation programme
through which Tetris Pharma intends to commercialise Ogluo(R) in
core European markets. The Company is currently in discussions with
various health authorities across Europe to ensure timely launches
in additional major European countries.
"In Austria, people living with diabetes will now be able to
receive Ogluo(R) to tackle severe hypoglycaemic events, enabling
patients and those around to them to act quickly when such an event
happens," said Dr Shafiq Choudhary, Managing Director of Tetris
Pharma, "With this launch in Austria, we look forward to expanding
our reach within Europe over the coming months to bring this new
treatment to people living with diabetes."
Enquiries:
Tetris Pharma
Shafiq Choudhary +44 (0)1628 337579
Notes to Editors
Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a
commercial-stage specialty pharmaceutical company with expertise in
registering, marketing, sales and the distribution of speciality
hospital products across the UK and Europe. Our experienced team
has a proven history of building and growing sales. Having secured
distribution rights for already licensed products across Europe, we
have a portfolio of niche injectable products including Ogluo(R) ,
a ready-to-use glucagon for emergency use to treat hypoglycaemia.
We collaborate with partners to provide patients with effective
treatments and quality healthcare by ensuring we deliver
accountability, partnership and performance.
For further information, please visit tetrispharma.com
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner, David Daley, Angela Email: arecor@consilium-comms.com
Gray
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABJMRTMTJMBIJ
(END) Dow Jones Newswires
January 04, 2023 02:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024